A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Primary pulmonary hypertension is a disease characterized by the progressive elevation of pulmonary-artery pressure and vascular resistance, ultimately producing right ventricular failure and death. 1 – 3 A variety of treatments have been used, including vasodilators, 4 – 7 anticoagulant agents, 6 ,...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1996-02, Vol.334 (5), p.296-301 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 301 |
|---|---|
| container_issue | 5 |
| container_start_page | 296 |
| container_title | The New England journal of medicine |
| container_volume | 334 |
| creator | Barst, Robyn J Rubin, Lewis J Long, Walker A McGoon, Michael D Rich, Stuart Badesch, David B Groves, Bertron M Tapson, Victor F Bourge, Robert C Brundage, Bruce H Koerner, Spencer K Langleben, David Keller, Cesar A Murali, Srinivas Uretsky, Barry F Clayton, Linda M Jöbsis, Maria M Blackburn, Shelmer D Shortino, Denise Crow, James W |
| description | Primary pulmonary hypertension is a disease characterized by the progressive elevation of pulmonary-artery pressure and vascular resistance, ultimately producing right ventricular failure and death.
1
–
3
A variety of treatments have been used, including vasodilators,
4
–
7
anticoagulant agents,
6
,
8
and lung or heart–lung transplantation,
9
–
13
but none have resulted in improved survival in a prospective, randomized trial.
Epoprostenol (formerly called prostacyclin or prostaglandin I
2
) is a potent, short-acting vasodilator and inhibitor of platelet aggregation that is produced by vascular endothelium. Short-term infusions of epoprostenol decrease pulmonary vascular resistance in a dose-dependent manner in patients with primary pulmonary hypertension, and . . . |
| doi_str_mv | 10.1056/NEJM199602013340504 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77973579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77973579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-ca2bc3af0941d42ea997b87b893d44fa52a61c07b79c556219315f9e321e0c053</originalsourceid><addsrcrecordid>eNp9kd9r2zAQx8VoabOsf8EYiDJGR3F7-mVbjyVkbUe75qF7NooiUwdb8iS7JU_913choQ-jTAh0x33uTt87Qj4zuGCg8stf85_3TOscODAhJCiQH8iEKSEyKSE_IBMAXmay0OKYfExpDXiY1EfkqFSCA1cT8npFZ6HrTWxS8DTU6Pmh8WMYE731QzTPzm_teR_6GNKAXkvPFlvT2I1tG_-dvjTD0zYP0aEJ3rT08clF029oHSJdxKYzcUMXY9thEK2bTe8iVkoIfyKHtWmTO9m_U_L7x_xxdpPdPVzfzq7uMqsKOWTW8KUVpgYt2UpyZ7QuliVeLVZS1kZxkzMLxbLQVqmcMy2YqrUTnDmwoMSUfNvVRRV_RpeGqmuSdW1rvEN9VVHoQiic1JSc_gOuwxhRVKo4FzqXOQeExA6yOIgUXV31O5UVg2q7m-qd3WDWl33pcdm51VvOfhkY_7qPm2RNW0fjbZPeMK7LUuIfpuR8h3Vdqrxbd_9t-hdgcaQX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223964620</pqid></control><display><type>article</type><title>A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Barst, Robyn J ; Rubin, Lewis J ; Long, Walker A ; McGoon, Michael D ; Rich, Stuart ; Badesch, David B ; Groves, Bertron M ; Tapson, Victor F ; Bourge, Robert C ; Brundage, Bruce H ; Koerner, Spencer K ; Langleben, David ; Keller, Cesar A ; Murali, Srinivas ; Uretsky, Barry F ; Clayton, Linda M ; Jöbsis, Maria M ; Blackburn, Shelmer D ; Shortino, Denise ; Crow, James W</creator><creatorcontrib>Barst, Robyn J ; Rubin, Lewis J ; Long, Walker A ; McGoon, Michael D ; Rich, Stuart ; Badesch, David B ; Groves, Bertron M ; Tapson, Victor F ; Bourge, Robert C ; Brundage, Bruce H ; Koerner, Spencer K ; Langleben, David ; Keller, Cesar A ; Murali, Srinivas ; Uretsky, Barry F ; Clayton, Linda M ; Jöbsis, Maria M ; Blackburn, Shelmer D ; Shortino, Denise ; Crow, James W ; Primary Pulmonary Hypertension Study Group</creatorcontrib><description>Primary pulmonary hypertension is a disease characterized by the progressive elevation of pulmonary-artery pressure and vascular resistance, ultimately producing right ventricular failure and death.
1
–
3
A variety of treatments have been used, including vasodilators,
4
–
7
anticoagulant agents,
6
,
8
and lung or heart–lung transplantation,
9
–
13
but none have resulted in improved survival in a prospective, randomized trial.
Epoprostenol (formerly called prostacyclin or prostaglandin I
2
) is a potent, short-acting vasodilator and inhibitor of platelet aggregation that is produced by vascular endothelium. Short-term infusions of epoprostenol decrease pulmonary vascular resistance in a dose-dependent manner in patients with primary pulmonary hypertension, and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199602013340504</identifier><identifier>PMID: 8532025</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Cardiovascular system ; Drug Administration Schedule ; Drug therapy ; Epoprostenol - administration & dosage ; Epoprostenol - adverse effects ; Exercise Tolerance - drug effects ; Female ; Hemodynamics - drug effects ; Humans ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - mortality ; Hypertension, Pulmonary - therapy ; Infusions, Intravenous ; Male ; Medical research ; Medical sciences ; Miscellaneous ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Prospective Studies ; Survival Analysis ; Treatment Outcome ; Vasodilator Agents - therapeutic use</subject><ispartof>The New England journal of medicine, 1996-02, Vol.334 (5), p.296-301</ispartof><rights>Copyright © 1996 Massachusetts Medical Society. All rights reserved.</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-ca2bc3af0941d42ea997b87b893d44fa52a61c07b79c556219315f9e321e0c053</citedby><cites>FETCH-LOGICAL-c574t-ca2bc3af0941d42ea997b87b893d44fa52a61c07b79c556219315f9e321e0c053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199602013340504$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223964620?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2988422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8532025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barst, Robyn J</creatorcontrib><creatorcontrib>Rubin, Lewis J</creatorcontrib><creatorcontrib>Long, Walker A</creatorcontrib><creatorcontrib>McGoon, Michael D</creatorcontrib><creatorcontrib>Rich, Stuart</creatorcontrib><creatorcontrib>Badesch, David B</creatorcontrib><creatorcontrib>Groves, Bertron M</creatorcontrib><creatorcontrib>Tapson, Victor F</creatorcontrib><creatorcontrib>Bourge, Robert C</creatorcontrib><creatorcontrib>Brundage, Bruce H</creatorcontrib><creatorcontrib>Koerner, Spencer K</creatorcontrib><creatorcontrib>Langleben, David</creatorcontrib><creatorcontrib>Keller, Cesar A</creatorcontrib><creatorcontrib>Murali, Srinivas</creatorcontrib><creatorcontrib>Uretsky, Barry F</creatorcontrib><creatorcontrib>Clayton, Linda M</creatorcontrib><creatorcontrib>Jöbsis, Maria M</creatorcontrib><creatorcontrib>Blackburn, Shelmer D</creatorcontrib><creatorcontrib>Shortino, Denise</creatorcontrib><creatorcontrib>Crow, James W</creatorcontrib><creatorcontrib>Primary Pulmonary Hypertension Study Group</creatorcontrib><title>A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Primary pulmonary hypertension is a disease characterized by the progressive elevation of pulmonary-artery pressure and vascular resistance, ultimately producing right ventricular failure and death.
1
–
3
A variety of treatments have been used, including vasodilators,
4
–
7
anticoagulant agents,
6
,
8
and lung or heart–lung transplantation,
9
–
13
but none have resulted in improved survival in a prospective, randomized trial.
Epoprostenol (formerly called prostacyclin or prostaglandin I
2
) is a potent, short-acting vasodilator and inhibitor of platelet aggregation that is produced by vascular endothelium. Short-term infusions of epoprostenol decrease pulmonary vascular resistance in a dose-dependent manner in patients with primary pulmonary hypertension, and . . .</description><subject>Adult</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Epoprostenol - administration & dosage</subject><subject>Epoprostenol - adverse effects</subject><subject>Exercise Tolerance - drug effects</subject><subject>Female</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - mortality</subject><subject>Hypertension, Pulmonary - therapy</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Prospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kd9r2zAQx8VoabOsf8EYiDJGR3F7-mVbjyVkbUe75qF7NooiUwdb8iS7JU_913choQ-jTAh0x33uTt87Qj4zuGCg8stf85_3TOscODAhJCiQH8iEKSEyKSE_IBMAXmay0OKYfExpDXiY1EfkqFSCA1cT8npFZ6HrTWxS8DTU6Pmh8WMYE731QzTPzm_teR_6GNKAXkvPFlvT2I1tG_-dvjTD0zYP0aEJ3rT08clF029oHSJdxKYzcUMXY9thEK2bTe8iVkoIfyKHtWmTO9m_U_L7x_xxdpPdPVzfzq7uMqsKOWTW8KUVpgYt2UpyZ7QuliVeLVZS1kZxkzMLxbLQVqmcMy2YqrUTnDmwoMSUfNvVRRV_RpeGqmuSdW1rvEN9VVHoQiic1JSc_gOuwxhRVKo4FzqXOQeExA6yOIgUXV31O5UVg2q7m-qd3WDWl33pcdm51VvOfhkY_7qPm2RNW0fjbZPeMK7LUuIfpuR8h3Vdqrxbd_9t-hdgcaQX</recordid><startdate>19960201</startdate><enddate>19960201</enddate><creator>Barst, Robyn J</creator><creator>Rubin, Lewis J</creator><creator>Long, Walker A</creator><creator>McGoon, Michael D</creator><creator>Rich, Stuart</creator><creator>Badesch, David B</creator><creator>Groves, Bertron M</creator><creator>Tapson, Victor F</creator><creator>Bourge, Robert C</creator><creator>Brundage, Bruce H</creator><creator>Koerner, Spencer K</creator><creator>Langleben, David</creator><creator>Keller, Cesar A</creator><creator>Murali, Srinivas</creator><creator>Uretsky, Barry F</creator><creator>Clayton, Linda M</creator><creator>Jöbsis, Maria M</creator><creator>Blackburn, Shelmer D</creator><creator>Shortino, Denise</creator><creator>Crow, James W</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19960201</creationdate><title>A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension</title><author>Barst, Robyn J ; Rubin, Lewis J ; Long, Walker A ; McGoon, Michael D ; Rich, Stuart ; Badesch, David B ; Groves, Bertron M ; Tapson, Victor F ; Bourge, Robert C ; Brundage, Bruce H ; Koerner, Spencer K ; Langleben, David ; Keller, Cesar A ; Murali, Srinivas ; Uretsky, Barry F ; Clayton, Linda M ; Jöbsis, Maria M ; Blackburn, Shelmer D ; Shortino, Denise ; Crow, James W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-ca2bc3af0941d42ea997b87b893d44fa52a61c07b79c556219315f9e321e0c053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Epoprostenol - administration & dosage</topic><topic>Epoprostenol - adverse effects</topic><topic>Exercise Tolerance - drug effects</topic><topic>Female</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - mortality</topic><topic>Hypertension, Pulmonary - therapy</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Prospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barst, Robyn J</creatorcontrib><creatorcontrib>Rubin, Lewis J</creatorcontrib><creatorcontrib>Long, Walker A</creatorcontrib><creatorcontrib>McGoon, Michael D</creatorcontrib><creatorcontrib>Rich, Stuart</creatorcontrib><creatorcontrib>Badesch, David B</creatorcontrib><creatorcontrib>Groves, Bertron M</creatorcontrib><creatorcontrib>Tapson, Victor F</creatorcontrib><creatorcontrib>Bourge, Robert C</creatorcontrib><creatorcontrib>Brundage, Bruce H</creatorcontrib><creatorcontrib>Koerner, Spencer K</creatorcontrib><creatorcontrib>Langleben, David</creatorcontrib><creatorcontrib>Keller, Cesar A</creatorcontrib><creatorcontrib>Murali, Srinivas</creatorcontrib><creatorcontrib>Uretsky, Barry F</creatorcontrib><creatorcontrib>Clayton, Linda M</creatorcontrib><creatorcontrib>Jöbsis, Maria M</creatorcontrib><creatorcontrib>Blackburn, Shelmer D</creatorcontrib><creatorcontrib>Shortino, Denise</creatorcontrib><creatorcontrib>Crow, James W</creatorcontrib><creatorcontrib>Primary Pulmonary Hypertension Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barst, Robyn J</au><au>Rubin, Lewis J</au><au>Long, Walker A</au><au>McGoon, Michael D</au><au>Rich, Stuart</au><au>Badesch, David B</au><au>Groves, Bertron M</au><au>Tapson, Victor F</au><au>Bourge, Robert C</au><au>Brundage, Bruce H</au><au>Koerner, Spencer K</au><au>Langleben, David</au><au>Keller, Cesar A</au><au>Murali, Srinivas</au><au>Uretsky, Barry F</au><au>Clayton, Linda M</au><au>Jöbsis, Maria M</au><au>Blackburn, Shelmer D</au><au>Shortino, Denise</au><au>Crow, James W</au><aucorp>Primary Pulmonary Hypertension Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1996-02-01</date><risdate>1996</risdate><volume>334</volume><issue>5</issue><spage>296</spage><epage>301</epage><pages>296-301</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Primary pulmonary hypertension is a disease characterized by the progressive elevation of pulmonary-artery pressure and vascular resistance, ultimately producing right ventricular failure and death.
1
–
3
A variety of treatments have been used, including vasodilators,
4
–
7
anticoagulant agents,
6
,
8
and lung or heart–lung transplantation,
9
–
13
but none have resulted in improved survival in a prospective, randomized trial.
Epoprostenol (formerly called prostacyclin or prostaglandin I
2
) is a potent, short-acting vasodilator and inhibitor of platelet aggregation that is produced by vascular endothelium. Short-term infusions of epoprostenol decrease pulmonary vascular resistance in a dose-dependent manner in patients with primary pulmonary hypertension, and . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>8532025</pmid><doi>10.1056/NEJM199602013340504</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1996-02, Vol.334 (5), p.296-301 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77973579 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adult Anticoagulants - therapeutic use Biological and medical sciences Cardiovascular system Drug Administration Schedule Drug therapy Epoprostenol - administration & dosage Epoprostenol - adverse effects Exercise Tolerance - drug effects Female Hemodynamics - drug effects Humans Hypertension Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - mortality Hypertension, Pulmonary - therapy Infusions, Intravenous Male Medical research Medical sciences Miscellaneous Pharmacology. Drug treatments Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Prospective Studies Survival Analysis Treatment Outcome Vasodilator Agents - therapeutic use |
| title | A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparison%20of%20Continuous%20Intravenous%20Epoprostenol%20(Prostacyclin)%20with%20Conventional%20Therapy%20for%20Primary%20Pulmonary%20Hypertension&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Barst,%20Robyn%20J&rft.aucorp=Primary%20Pulmonary%20Hypertension%20Study%20Group&rft.date=1996-02-01&rft.volume=334&rft.issue=5&rft.spage=296&rft.epage=301&rft.pages=296-301&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199602013340504&rft_dat=%3Cproquest_cross%3E77973579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223964620&rft_id=info:pmid/8532025&rfr_iscdi=true |